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Summary
Introduction. The automatic suspension of the insulin pump and discontin-
uation of insulin delivery in case of hypoglycemia is one of the features of 
Veo insulin pump when it is connected with the sensor used for continuous 
monitoring of glycemia (CGM). This type of therapy is currently considered 
to be the best one for achieving a good metabolic control in children with 
type 1 diabetes mellitus. The objective of the study was to check whether 
the use of an option for automatic suspension in case of hypoglycemia and 
combined bolus affects the metabolic control in children with type 1 diabe-
tes mellitus using the insulin pump for a three-month period.
Methods. The study included 25 participants (13 girls and 12 boys), aged 
7 to 15 years with average age 11.88 ± 3.15 years and average diabetes du-
ration of 6.12 ± 2.5 years. On average, the participants have already been 
using the insulin pump Paradigm Veo TM MMT-754 for 3.08 ± 1.73 years. 
The measurements of HbA1c were done at the beginning of the study, then 
after three and six months. 
Results. The percentage of glucose serum levels above 7.8 mmol/L insig-
nificantly increased, while the percentage of glucose serum levels below 
3.9 mmol/L decreased during the three-month period  of CGM wearing. 
The initial HbA1c was 7.53 ± 0.87%.  After three months of wearing, CGM 
HbA1c showed a slight decrease to 7.48 ± 0.73%, while at the follow-up af-
ter another three months without CGM HbA1c increased to 7.57 ± 0.98%. 
Conclusion. This study shows that the use of an insulin pump with the op-
tion of automatic suspension in case of hypoglycemia and combined bo-
lus is only associated with a certain improvement in the metabolic control 
after three months of continuous wearing without increasing the risk of 
hypoglycemia.
Key words: type 1 diabetes mellitus, children, Veo insulin pump, continuous 
glucose monitoring (CGM). 
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Introduction
Insulin pump therapy is considered to be an 
optimal type of insulin therapy in children 
with type 1 diabetes mellitus, since it resem-
bles the physiological need for insulin during 
24 hours. The insulin pump Veo in the combi-
nation with a continuous glucose monitoring 
(CGM) is a particularly effective way to apply 
insulin therapy because it automatically sus-
pends supply of basal insulin in case of hypo-
glycemia. This option significantly reduces the 
severity and duration of hypoglycemic events 
simultaneously enabling the metabolic control 
of children with diabetes [1]. With regard to 
this, it was important to note that although 
HbA1c measurement is an objective method 
of assessing the long-term metabolic control 
over three last months, common hypoglycemia 
events could cause lower HbA1c levels, which 
would give a false picture of a good metabol-
ic control. On the other side, it is well-known 
that both hypoglycemia and fear of it represent 
obstacles to achieving good metabolic control.
CGM refers to the interstitial glucose mea-
surement every five minutes, which provides 
a detailed set of information including glucose 
variability and trends, as well as estimates of 
HbA1c. There are studies confirming that a 
longer use of CGM is advantageous compared 
to shorter periods of use, because its contin-
uous use provides patients with insights on 
the glycemic dynamics which consequently 
improves long-lasting glycemic control with 
or without effects on hypoglycemia [2, 3]. For 
instance, the STAR3 study showed that us-
ing CGM together with the insulin pump led 
to a significant reduction in HbA1c by 0.6% 
(p < 0.001) compared with the group that used 
multiple insulin injections instead of pump 
during 12 to 18 months of following [3]. More-
over, in the SWITCH study the use of CGM 
control together with the insulin pump ther-
apy resulted both in a decrease in HbA1c and 
a reduction in time spent in hypoglycemia [4, 
5].  Ly and coworkers [6] compared standard 
insulin pump therapy with sensor augmented 
pump (SAP) therapy and low-glucose suspend 
(LGS) option on pumps, and found that this 
addition reduced severe and moderate hypo-
glycemia during 6 months of treatment. The 
first long-term study of efficacy and safety of 
insulin pump therapy with both SAP and LGS, 
which lasted for 47 months, showed a signif-
icant and sustained decrease in HbA1c and a 
reduction in hypoglycemic events [7]. Further-
more, in the ASPIRE study, using an option to 
automatically stop the delivery of insulin when 
close to hypoglycemia resulted in a decrease 
in the frequency and duration of nocturnal 
hypoglycemia without increasing HbA1c [8-
10].  Also, several studies showed that safety 
and efficacy as well as satisfaction and toler-
ance of CGM were maintained at long-term 
follow up [11, 12]. 
The main aim of our study is to determine 
whether the capabilities of the VEO insulin 
pump, used together with the CGM device 
with automatic suspension in the event of hy-
poglycemia, affects the metabolic control in 
children with type 1 diabetes mellitus wear-
ing insulin pumps. In addition, our objectives 
were to investigate whether patients would 
adhere to the recommended protocol in case 
of a hypoglycemic event and whether they 
would use the combined boluses when con-
suming highly caloric and fatty meals, which 
make a significant proportion of the tradition-
al cuisine of the area. 
Methods
The study was conducted at the Clinic for Chil-
dren’s Diseases, University Clinical Center in 
Banja Luka (The Republic of Srpska, Bosnia 
and Herzegovina) from January to June 2017. 
The study was approved by the Ethics Com-
mittee of Human Experimentation in Bosnia 
and Herzegovina. The participants were 25 
children with type 1 diabetes mellitus, 12 boys 
and 13 girls, aged 7 to 16 years (with average 
age 11.88 ± 3.15 years and average diabetes 
duration 6.12 ± 2.5 years). All patients were 
using the insulin pump Paradigm Veo TM 
MMT-754 for 3.08 ± 1.73 years.
All participants and/or their parents or 
guardians had signed the consent for conduct-
ing research and they agreed to regularly come 
to check-ups to read the data from the insulin 
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pump and to discuss them with the researchers 
in order to improve the quality of the thera-
py. Each patient was equipped with CGM that 
included a glucose sensor (Enlite TM glucose 
sensor) with the Medtronic MiniLink trans-
mitter, which sends data from the sensor to 
the screen at the pump. All participants used 
the Wizard option of the insulin pump Veo 
on the daily basis respecting the Dusseldorf 
model for carbohydrates calculation. 
Prior to the beginning of the study the trans-
mitter’s mode of operation was explained to the 
participants and we explained the rules to be 
followed during wearing, which also includ-
ed calibrating the sensor minimally four times 
daily. In addition, the meaning of the alarm 
and the procedures to be followed in the case 
of an alarm were explained to the patients. It 
is important to mention that all participants 
were able to see at any time the current value 
of glycemia, based on readings from the sen-
sors. All participants had carried continuously 
CGM for three months during which we aimed 
to improve their glycemic profiles and reduce 
glycemic variability. At the regular monthly 
check-ups, we also tested whether the param-
eters of the pumps were correct. 
In all patients on the insulin pump, hypo-
glycemia was defined as a blood glucose con-
centration of less than 3.9 mmol/L, while hy-
perglycemia was considered a blood glucose 
concentration higher than 7.8 mmol/L. The 
beginning of the study was marked by the 
measurement of HbA1c (done at the 
University Clinical Center Banja Luka 
on Cobas E601, the Roche apparatus) 
and installment of CGM for the period 
of three months. At the same day the 
demographical (age, sex, weight and 
height) and the clinical (basal and bo-
lus insulin doses) data were collected. 
After the first month, data were read 
from the insulin pump, the glycemic 
values  were discussed, basal and bolus 
insulin doses and carbohydrate ratios 
were adjusted if needed. The same ac-
tivity was repeated after the second and 
third month. During the whole time of 
the study, the patients were in constant 
contact with the doctor in case of nec-
essary consultations. After three months, the 
measurement of HbA1c was repeated. After-
wards children worn an insulin pump with-
out the sensors for the next three months. We 
again measured HbA1c after three months.
Statistical analysis. Data were analyzed us-
ing descriptive (frequencies and percentages 
for categorical variables, and central tendency 
and variability measures for numerical vari-
ables) and inferential statistics. Nonparametric 
inferential techniques were used when signif-
icant distribution asymmetry or existence of 
extreme scores were observed: for instance, 
in such cases the Friedman test was used in-
stead of a repeated measures analysis of vari-
ance which was a preferred technique for de-
tecting a statistical change. All analyses were 
performed using the statistical software IBM 
Statistical Package for the Social Sciences (Ver-
sion 21; SPSS). 
Results
The demographic characteristics of the partic-
ipants are shown in Table 1. One can see that, 
based on age range, it consisted of two sub-
groups with a balanced gender ratio. All par-
ticipants were examined for the time period 
of 2139 days out of which they were wearing 
CGMs for 1702 days, i.e. 79.6% of the time. In 
the first month this percentage was highest 
(around 85% of the time). These results indi-
Number of participants (n) 25
Girls (n) 12
Age, years 11.88±3.15
    Number of participants age 7 - 11 13 (Girls: 5)
    Number of participants age 12 - 16 12  (Girls: 7)
Years since the diagnosis of diabetes 6.12±2.5
Years on insulin pump therapy 3.08±1.73
BMI, kg/m2 19.88±3.74
HbA1c% at baseline 7.53±0.87
HbA1c%  after 3 months 7.48±0.73
HbA1c%  after 6 months 7.57±0.98
Table 1. Demographic characteristics of the study participants.
Data are presented as number and as mean ± SD.
BMI = Body mass index, HbA1c = glycated hemoglobin
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cate that our patients were largely willing and 
motivated to cooperate during the examina-
tion period. 
As can be seen from Table 1, wearing CGM 
for three months resulted in only a slight de-
crease in HbA1c. After that period, not wear-
ing CGM resulted in an increase in HbA1c to 
a negligibly higher level than what was ob-
served at baseline. Overall, these changes did 
not reach the level of statistical significance 
(Friedman test, p = 0.603). 
Table 2 shows that the majority of partici-
pants made more than 6 measurements daily 
over the course of the study. The percentage of 
measures spent in glycemia above 7.8 mmol/L 
slightly increased over a three-month period 
during which the patients wore CGM, reach-
ing a peak in the third month. This was not 
a statistically significant change (p = 0.430). 
On the other hand, out of the total number 
of measures, the percentage of glycemic lev-
els below 3.9 mmol/L decreased constantly, 
while wearing CGM: from 2.50% during the 
first month to 1.85% during the third month. 
Again this was not statistically significant 
(p = 0.430). It is, however, important to stress 
that during the study neither a serious hypo-
glycemic episode nor a diabetic ketoacidosis 
case were reported. The area under the curve 
of serum glucose values (AUC) showed only 
a small variability throughout the study with 
the changes being far from either a statistical 
or clinical significance. 
Table 3 shows that the use of the low glu-
cose suspend option increased both during the 
day and during the night over three months, 
with total number of uses being almost double 
during the day compared to during the night. 
The number of discontinued options during 
the day was twice as high compared to the low 
glucose suspend use overnight, resulting in 
increased recurrent hypoglycemia during the 
day. The number of reactive hyperglycemia 
during the day was more frequent than reactive 
hyperglycemia over night. Also, the number 
of recurrent hypoglycemia and the number of 
hypoglycemia due to bolus was visibly higher 
during daytime than overnight. We also ob-
served that some children corrected their hy-
poglycemia with carbohydrates, after which 
they gave themselves an insulin bolus which 
created a new hypoglycemia. Furthermore, a 
greater number of suspension options were re-
corded during the day than during overnight, 
which could be explained by the fact that chil-
dren did not wear their insulin pumps during 
their physical activities or when taking bath. 
Table 3 also shows that the number of low 
glucose suspend options increased over the 
course of the study, whereas the number of 
suspensions excluding the low suspend option 
and the number of interrupted low suspend 
options decreased. 
Through CareLink Pro software we ob-
Variable Month 1 Month 2 Month 3 p
Days in the study 27.56±7.34 28.94±7.03 29.04±7.96 0.687
Days on CGM 23.60±6.60 22.24±5.50 22.24±6.34 0.679
Number of measures on glucometer per day 7.4 [5.7, 9.3] 6.6 [5.6, 8.8] 7.2 [6.3, 10.4] 0.722
Number of measures on glucometer 214.2±100.2 209.3±69.3 227.6±95.1 0.591
% of glucometer measured values above 7.8 mmol/l 56.15±18.85 58.38±17.42 59.56±16.03 0.430
% of glucometer measured values below 3.9 mmol/l 2.54±3.42 2.08±2.83 1.85±3.22 0.349
Glucose value from glucometer, mmol/L 9.55±1.97 9.65±1.88 9.55±1.63 0.893
Glucose value from sensor, mmol/L 8.71±1.34 8.70±1.22 8.72±1.06 0.995
AUC above 7.8 mmol/l 1.94±1.00 1.86±0.78 1.93±0.75 0.839
AUC below 3.9 mmol/l 0.03±0.03 0.04±0.04 0.04±0.03 0.455
Table 2. Description of general glucometer and sensor data. 
CGM = Continuous glucose monitoring. AUC = Area under the curve. Results are presented as mean ± SD with respective p-values obtai-
ned through repeated measures analysis of variance, except for the number of measures of glucometer per day for which median values with 
lower and upper quartiles were presented accompanied by p-values obtained through the Friedman’s test.
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tained a record of glycemic variability of eight 
critical periods of the day. These periods were 
defined as follows: an hour before a regular 
meal and two hours after a meal, with break-
fast being defined as time between 06:00 - 10:00, 
lunch 11:00 - 15:00, dinner 16:00 - 22:00, awak-
ening time 05:00 - 09:00, and bedtime period 
20:00 - 00:00. For these time periods the aver-
age values were calculated by the software. 
Table 4 shows that there were no notice-
able systemic trends in change of glucose val-
ues over the course of the study (all p-values 
> 0.10). Overall, this finding suggests that our 
patients did not change much their nutrition 
habits and that they probably retained their 
eating habits from the period before baseline. 
The lack of changes in carbohydrate intake 
further supports this assumption (Table 5).
Table 5 shows that the total insulin dosage 
did not change significantly over the course of 
the study. However, basal-bolus insulin ratio 
changed somewhat with the increase in basal 
insulin (39.6% to 42.5%, p < 0.10) and the de-
crease of bolus insulin (from 60.1% to 58.7%). 
All participants tended to use a bolus Wizard 
option, and only rarely gave themselves bolus 
insulin manually. It can be said that they ad-
hered well to the recommendations from the 
Variable Month 1 Month 2 Month 3 p
Number of LGS during day 9.72±9.77 10.20±10.01 10.08±8.88 0.840
Number of LGS during night 4.64±4.80 5.44±5.08 5.52±4.11 0.368
Number of suspend without LGS during day 2.52±3.34 1.80±2.18 1.48±2.00 0.174
Number of suspend without LGS during night 0.48±0.77 0.32±0.90 0.52±1.05 0.223
Number of times when LGS event was interrupted by participant by day 9.44±9.66 9.64±9.95 8.72±7.77 0.660
Number of times when LGS event was interrupted by participant by night 3.52±4.11 4.20±4.72 3.88±2.95 0.729
Number of hyperglycemic events after hypoglycemic events by day 2.72±2.03 2.64±2.33 2.52±3.57 0.220
Number of hyperglycemic events after hypoglycemic events by night 0.80±1.04 0.76±1.03 0.92±1.73 0.455
Total number of hypoglycemic events 17.36±13.22 18.04±12.57 17.24±12.12 0.424
Repeated hypoglycemic events by day 1.28±1.81 0.92±1.26 1.24±1.64 0.768
Repeated hypoglycemic events by night 0.40±1.00 0.72±1.28 0.80±1.35 0.068
Hypoglycemic events caused by bolus by day 3.48±3.70 4.00±7.05 3.68±3.59 0.952
Hypoglycemic event caused by bolus by night 0.80±1.08 1.20±1.66 1.04±1.40 0.591
Number of hours when pump was suspended per participant 31.56±27.65 26.03±16.12 28.05±18.30 .852
Table 3. Characteristics of recorded hypoglycemic events. 
Results are presented as mean ± SD. P-values were obtained through Friedman’s test.  
LGS = low glucose suspend 
Measurement period Month 1 Month 2 Month 3 p
Waking up 9.25±1.89 9.22±1.84 9.16±1.53 0.960
Before breakfast 8.17±2.01 8.53±2.24 8.29±1.58 0.524
After breakfast 9.88±2.78 10.15±2.83 10.18±2.09 0.780
Before lunch 8.04±1.89 8.40±1.94 8.00±1.24 0.276
After lunch 9.65±2.54 8.72±2.02 9.34±2.14 0.135
Before dinner 8.42±2.42 8.87±2.04 9.16±2.33 0.651
After dinner 9.40±2.23 9.02±1.76 9.06±1.95 0.605
Bedtime 9.56±2.21 9.93±2.35 9.87±2.29 0.633
Table 4. Mean glucose levels (mmol/L) disaggregated by a critical period of the day
Results are presented as mean ±  SD. P-values were obtained through repeated measures 
analysis of variance.
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wizard program, because they accepted the 
insulin dosage in more than 95% of the cas-
es. The use of dual-square bolus constantly 
increased over the course of the study (from 
12.4% to 15.4%), which actually was aimed to 
happen. On the other side, the insulin-carbo-
hydrates ratio did not change significantly, 
thus suggesting that initial settings were ap-
propriate for the patients. 
Discussion 
This is the first study conducted on the terri-
tory of Bosnia and Herzegovina in patients 
with type 1 diabetes mellitus who had used 
the insulin pump Veo together with the CGM 
for the time period of three months. The study 
had multiple aims. First of all, we wanted to 
examine whether the use of the VEO insulin 
pump, used together with the CGM device 
with automatic suspension in the event of hy-
poglycemia, affects the metabolic control in 
children with type 1 diabetes. We measured 
this not only via HbA1c, but also consider-
ing hypoglycemic data. Although we found 
only a negligible and insignificant decrease 
in HbA1c, the results are still encouraging. 
Namely, during the period of the study the 
Variable Month 1 Month 2 Month 3 p
Total insulin, IU 40.13±15.91 40.46±16.71 39.87±15.37 0.818
Basal insulin, IU 15.78±7.55 16.39±7.65 16.62±7.54 0.010
Basal, % 39.60±9.19 41.43±8.67 42.54±12.52 0.091
Bolus insulin, IU 24.28±10.32 23.52±10.63 23.55±10.00 0.556
Bolus, % 60.12±9.12 59.13±9.33 58.67±9.00 0.215
Carbohydrate intake, g 221.52±99.92 210.68±81.12 218.34±80.50 0.535
Insulin to CH ratio, IU/g 10.02±4.48 9.73±4.36 10.04±3.70 0.780
Bolus Wizard event (per day) 7.04±2.84 6.90±2.85 6.71±2.63 0.444
Manual bolus event (per day) 0.42±1.25 0.42±1.29 0.38±1.24 0.216
Dual/Square bolus (total number) 12.36±17.57 14.88±26.71 15.40±23.57 0.422
Table 5. Insulin dosage, basal and bolus events during the study
CH = Carbohydrates. Results are presented as mean ± SD. P-values were obtained through repeated measures 
analysis of variance or Friedman’s test where appropriate. 
number of hypoglycemia did not increase. On 
the contrary, there was a small, albeit insignif-
icant, decrease in hypoglycemic events over 
the course of the study, without any serious 
hypoglycemic episode or diabetic ketoacido-
sis events. When it comes to HbA1c levels, in 
a study conducted by Battelino et al. [5], the 
use of CGM for 6 months led to a reduction in 
HbA1c, and a period without CGM led to the 
increase in HbA1c. It might be the case that the 
period of wearing CGM was too short in our 
study to establish the needed habits to improve 
metabolic control. Another explanation for 
the lower reduction in HbA1c in our subjects 
compared to other studies is possibly due to 
an average lower Hba1c that our respondents 
had at the beginning of the study.
In addition, we wanted to examine to which 
degree the patients accepted wearing the pump 
and adhered to hypoglycemia algorithms. We 
also wanted to determine the use of dual/
square bolus, particularly when consuming tra-
ditional meals of our region which are known 
to be highly caloric with simultaneously high 
levels of fat, protein and carbohydrates (i.e. 
pies, pizzas). With regard to this, we found 
that our participants used CGM for over 79.6% 
of time during three months which suggests 
that they accepted wearing it very well. Still, 
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when it comes to hypoglycemia algorithms, 
it is important to note that our participants 
sometimes interrupted the low glucose sus-
pend option before the period without insu-
lin ended. The patients then decided on their 
own to return to basal insulin, because they 
feared that they would enter hyperglycemia. 
This happened somewhat more often during 
the first two months of the study, and it is ob-
vious that users did not allow the algorithm to 
work as intended, even though the researchers 
educated the patients to let the low suspend 
glucose option of the pump in function. 
We must also add that, as clinicians, we 
observed several more advantages of using 
CGM: for example, bolus insulin was used 
more frequently and basal rates were more 
often modified in accordance to glucose lev-
els. Also, we gained significantly more insight 
into patients’ habits. For example, our patients 
often violated our advice and guidelines by 
correcting hypoglycemia both with carbohy-
drates ingestion and simultaneously with a 
certain dose of insulin. We can also confirm 
the findings of the SWITCH study that when 
the patients are provided with both a pump 
and a sensor, they are more involved in met-
abolic control by more frequently measuring 
their glycemia and by using more advanced 
options given in their pumps [5].
On the whole, the results of our study re-
sembled to what was found in the ASPIRE in 
home study which examined the effectiveness 
of the added threshold-suspend feature com-
pared to a standard sensor-augmented insu-
lin-pump therapy [8]. The ASPIRE study was 
similar both in length and with regard to the 
results to our study since it showed reduction 
in nocturnal hypoglycemia without improv- 
ing the HbA1c values compared to the control 
group. Nevertheless, we must state that the 
ASPIRE study had a better methodological 
design with a control group and better statis-
tical power (in total 247 patients participated 
in it). Still, we believe that our study makes a 
contribution to regional research on the effec-
tiveness of metabolic control via threshold-sus-
pend feature in insulin pumps. 
Conclusion
To summarize, the use of an insulin pump 
with CGM for three months only negligibly 
improved metabolic control after three months, 
but importantly, we have not observed in-
crease in hypoglycemic events. At the same 
time, the use of CGM made it possible to use 
insulin pump more efficiently, with more bo-
luses given throughout the day, more frequent 
use of temporary basal option, use of the low 
glucose suspend option, the use of combined 
bolus, but also more frequent self-control of 
glycemia compared to the usual numbers. We 
also observed that children with CGM were 
more involved around the insulin pump than 
in the absence of CGM. Interestingly, patients 
relied on the Wizard option, but we also no-
ticed their frequent manual suspensions of the 
pump. This decision was motivated by the fear 
of later hyperglycemia stemming from the ha-
bitual reliance on provided measures. Finally, 
we should be reminded that the subsequent 
use of an insulin pump without CGM result-
ed in a negligible deterioration of metabol-
ic control, but also in less frequent relevant 
self-adjustments to the insulin pump. In sum, 
we may conclude that although wearing CGM 
for three months might not dramatically im-
prove usual measures of metabolic control, it 
seems that it contributes to better acceptance 
of the pumps, better adherence to algorithms 
for hypoglycemia and more frequent use of 
combined bolus. 
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Efekat upotrebe insulinske pumpe sa opcijom prekida rada u slučaju 
hipoglikemije na metaboličku kontrolu djece sa tipom 1 dijabetes melitusa 
Gordana Bukara-Radujković1,2, Vesna Miljković2
1Univerzitetski klinički centar Republike Srpske, Klinika za dječje bolesti, Banja Luka,  
Republika Srpska, Bosna i Hercegovina
2Univerzitet u Banjoj Luci, Medicinski fakultet, Banja Luka, Republika Srpska, Bosna i Hercegovina
Uvod. Automatsko isključenje insulinske pumpe i prekidanje isporuke insulina u slučaju hipoglikemije je karak-
teristika insulinske pumpe Veo kada je povezana sa sistemom za kontinuirano mjerenje glikemije. Takva vrsta 
terapije je najbolji vid za postizanje dobre metaboličke kontrole djece oboljele od tipa 1dijabetes melitusa. Cilj je 
provjeriti da li je moguće korišćenjem opcije automatskog isključenja insulinske pumpe, u slučaju hipoglikemije, 
i kombinovanih bolusa za obroke, uticati na metaboličku kontrolu djece oboljele od tipa1dijabetesa melitusa. 
Metode.  Studija je obuhvatila 25 učesnika (13 djevojčica i 12 dječaka) uzrasta od 7 do 15 godina, prosječne 
starosti 11,88 ± 3,15 godina i prosječnog trajanja dijabetesa 6,12 ± 2,5 godina. U prosjeku, učesnici studije su 
već koristili insulinsku pumpu Paradigm Veo TM MMT-754 tokom 3,08 ± 1,73 godine. HbA1c je mjeren na po-
četku studije, nakon tri i šest mjeseci. 
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Rezultati. Procenat registrovanih vrednosti glikemije iznad 7,8 mmol/L je neznačajno porastao, dok je procenat 
glikemije ispod 3,9 mmol/L smanjen tokom tromjesečnog nošenja sistema za kontinuirano mjerenje glikemije. 
Početni HbA1c je iznosio 7,53 ± 0,87%. Nakon tri mjeseca nošenja glukoznog senzora HbA1c se neznatno sma-
njio na 7,48 ± 0,73 %, dok je nakon sljedeća tri mjeseca bez glukoznog senzora HbA1c porastao na 7,57 ± 0,98%. 
Zaključak. Ova studija pokazuje da upotreba insulinske pumpe sa opcijom automatskog isključenja u sluča-
ju hipoglikemije i kombinovanih bolusa je povezana sa blagim poboljšanjem metaboličke kontrole nakon tri 
mjeseca kontinuiranog nošenja bez porasta rizika od hipoglikemije. 
Ključne riječi: dijabetes melitus tip 1, djeca, insilinska pumpa Veo, kontinuirani monitoring glikemije 
